Skip to main content

Advertisement

SpringerLink
Log in

Central nervous system involvement in rheumatoid arthritis: possible role of chronic inflammation and tnf blocker therapy

  • Original Article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic disease, the etiology of which has yet to be clarified, which causes activation of proinflammatory pathways that bring about joint and systemic inflammation. Although peripheral nervous system anomalies are observed widely in RA, very few case reports on changes in the central nervous system (CNS) have been published. In recent years, the pathophysiology of CNS involvement that can occur in RA has attracted a great deal of attention. Emphasis has focused on the possibility that CNS involvement occurs due to blood–brain barrier (BBB) damage associated with chronic inflammation. The present study was performed to investigate the possible effects of BBB dysfunction and tumor necrosis factor (TNF) blocker therapy on BBB function, which may cause CNS damage in patients with RA. 58 RA patients [47 (81.0%) females, 11 (19.0%) males] and 34 healthy controls [24 (70.6%) females, 10 (29.4%) males] were included in the study. All RA patients were on synthetic DMARD therapy at the beginning. Thirty patients continued DMARD therapy, and 28 patients with high disease activity were started on TNF blocker therapy. All demographic characteristics of the patients were recorded. Disease activity was evaluated using the Disease Activity Score 28-joint count C reactive protein. The Mini-Mental State Examination was used to evaluate cognitive function, and the Fazekas scale was used to assess cranial lesions visualized by magnetic resonance imaging (MRI). Patients’ peripheral blood S100β, glial fibrillary acidic protein (GFAP), claudin, interleukin (IL)-17, and IL-1β levels were measured at the beginning of the study and after 6 months. Demographic characteristics (including sex, age, and body mass index) were similar in the RA and control groups. S100β and GFAP levels were significantly higher in the patient group than in the control group. In the group that was started on TNF blocker therapy, S100β and GFAP levels were significantly decreased 6 months after commencement of treatment. No difference was observed between the RA and control groups in terms of hyperintense lesions seen on cranial MRI. The S100β levels increased with lesions in the deep white matter seen on cranial MRI in patients with RA. In conclusion, next to decreasing disease activity and joint erosions by suppressing inflammation, anti-TNF therapy in RA can also suppress potential CNS involvement linked to BBB (blood–brain barrier) dysfunction. Further studies with broader participation and longer patient follow-up are needed to reinforce this hypothesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219

    Article  CAS  Google Scholar 

  2. Watson P, Fekete J, Deck J (1977) Central nervous system vasculitis in rheumatoid arthritis. Can J Neurol Sci 4:269–272

    Article  CAS  Google Scholar 

  3. Paci R, Giuffrida CM, Marangolo M, Ventura F (1983) Di Paola F (1983) Neuroradiologic picture of cerebral vasculitis in rheumatoid arthritis. Neuroradiology 25:343–345

    Article  CAS  Google Scholar 

  4. Ishizuka T, Suzuki K, Hara M, Kitani A, Kawagoe M, Nakamura H, Tsuchiya K (1992) Detection of intracranial lesions of rheumatoid vasculitis with magnetic resonance imaging (MRI). Ryumachi 32:19–26

    CAS  PubMed  Google Scholar 

  5. Chowdhry V, Kumar N, Lachance DH, Salomao DR, Luthra HS (2005) An unusual presentation of rheumatoid meningitis. Neuroimaging 15:286–288

    Article  Google Scholar 

  6. Caballol Pons N, Montalà N, Valverde J, Brell M, Ferrer I, Martínez-Yélamos S (2010) Isolated cerebral vasculitis associated with rheumatoid arthritis. Joint Bone Spine 77:361–363

    Article  Google Scholar 

  7. Banks WA, Robinson SM (2010) Minimal penetration of lipopolysaccharide across the murine blood–brain barrier. Brain Behav Immun 24:102–109

    Article  CAS  Google Scholar 

  8. Pan W (2002) Kastin, A.J.TNFa transport across the blood–brain barrier is abolished in receptor knockout mice. Exp Neurol 174:193–200

    Article  CAS  Google Scholar 

  9. Nishioku TL, Furusho K, Tomita A, Ohishi H, Dohgu S, Shuto H, Yamauchi A, Kataoka Y (2011) Potential role for S100A4 in the disruption of the blood–brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis. Neuroscience. 189:286–292

    Article  CAS  Google Scholar 

  10. Nishioku TL, Dohgu S, Takata F, Eto T, Ishikawa N, Kodama KB, Nakagawa S, Yamauchi A, Kataoka Y (2009) Detachment of brain pericytes from the basal lamina is involved in disruption of the blood-brain barrier caused by lipopolysaccharide-induced sepsis in mice. Cell Mol Neurobiol 29:309-316

    Article  CAS  Google Scholar 

  11. Nishioku T, Yamauchi A, Takata F, Watanabe T, Furusho K, Shuto H, Dohgu S, Kataoka Y (2010) Disruption of the blood–brain barrier in collagen-induced arthritic mice. Neurosci Lett 482:208–211

    Article  CAS  Google Scholar 

  12. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao Y, Lukanidin E (2001) The metastasis associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 20:4685–4695

    Article  CAS  Google Scholar 

  13. Bao LL, Zhu Y, Elhassan AM, Wu Q, Xiao B, Zhu J, Lindgren JU (2001) Adjuvant induced arthritis: IL-1 beta, IL-6 and TNF-alpha are up-regulated in the spinal cord. Neuroreport 12:3905–3908

    Article  CAS  Google Scholar 

  14. Hamed Sherifa A, Selim Zahra I, Elattar Amal M, Elserogy Yasser M, Ahmed Eman A, Mohamed Hanan O (2012) Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis. Clin Rheumatol 31:123–132

    Article  Google Scholar 

  15. Goncalves CA, Leite MC, Nardin P (2008) Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 41:755–763

    Article  CAS  Google Scholar 

  16. Germano AF, Tomasello F (2001) Blood–brain barrier permeability changes after subarachnoid haemorrhage: an update. Clinical implications, experimental findings, challenges and future directions. Springer, New York, pp 5–18

    Book  Google Scholar 

  17. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108

    Article  Google Scholar 

  18. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J et al (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68:954–960

    Article  CAS  Google Scholar 

  19. Al-Rajeh S, Ogunniyi A, Awada A, Daif A, Zaidan R (1999) Preliminary assessment of an Arabic version of the Mini-Mental state examination. Ann Saudi Med 19:150–152

    Article  CAS  Google Scholar 

  20. Folstein MF, Folstein SE, McHugh PH (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  CAS  Google Scholar 

  21. Kim GM, Park KY, Avery R et al (2014) Extensive leukoaraiosis is associated with high early risk of recurrence after ischemic stroke. Stroke 45:479–485

    Article  Google Scholar 

  22. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol 149:351–356

    Article  CAS  Google Scholar 

  23. Waisman A, Hauptmann J, Rgen T (2015) The role of IL-17 in CNS disease. Acta Neuropathol 129:625–637

    Article  CAS  Google Scholar 

  24. D’Mello C, Le T, Swain MG (2009) Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor—signaling during peripheral organ inflammation. J Neurosci 29:2089–2102

    Article  Google Scholar 

  25. Mellor R (1959) Cellular origin of rheumatoid factor. J Exp Med 110:875–876

    Article  Google Scholar 

  26. Markenson JA, McDougal JS, Tsairis P, Lockshin MD, Christian CL (1979) Rheumatoid meningitis: a localized immune process. Ann Intern Med 90:786–789

    Article  CAS  Google Scholar 

  27. Inan AS, Masatlioglu S, Ozyurek SC, Engin D, Erdem I (2011) Unusual central nervous system involvement of rheumatoid arthritis: success- ful treatment with steroid and azathioprine. Rheumatol Int 31:1383–1385

    Article  Google Scholar 

  28. Teeling JL, Carare RO, Glennie MJ, Perry VH (2012) Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. Acta Neuropathol 2012(124):479–490

    Article  Google Scholar 

  29. Rech J, Hess A, Finzel S, Kreitz S, Sergeeva M, Englbrecht M et al (2013) Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. Arthritis Rheum 65:325–333

    Article  CAS  Google Scholar 

  30. Skelly DT, Hennessy E, Dansereau MA, Cunningham C (2013) A systematic analysis of the peripheral and CNS effects of systemic LPS, IL. 1beta, TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS One 2013(8):e69123

    Article  Google Scholar 

  31. Thomson CA, McColl A, Cavanagh J, Graham GJ (2014) Peripheral inflammation is associated with remote global gene expression changes in the brain. J Neuroinflammation 11:73

    Article  Google Scholar 

  32. Chou R, Kane M, Ghimire S, Gautam S (2010) Tumor necrosis factor inhibition reduces the incidence of Alzheimer’s disease in rheumatoid arthritis patients. American College of Rheumatology, Atlanta

    Google Scholar 

  33. Detrait ER, Danis B, Lamberty Y, Foerch P (2014) Peripheral administration of anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int 72:10–13

    Article  CAS  Google Scholar 

  34. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S et al (2011) Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 108:3731–3736

    Article  CAS  Google Scholar 

  35. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA (2014) Neurological adverse events in patients receiving anti. TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16:125

    Article  Google Scholar 

  36. Bosch X, Saiz A, Ramos-Casals M, BIOGEAS Study Group (2011) Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 7:165–172

    Article  CAS  Google Scholar 

  37. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL et al (2011) Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 342:352–355

    Article  Google Scholar 

  38. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A et al (2013) Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013:671935

    CAS  PubMed  PubMed Central  Google Scholar 

  39. King KS, Peshock RM, Rossetti HC, McColl RW, Ayers CR, Hulsey KM et al (2014) Effect of normal aging versus hypertension, abnormal body mass index, and diabetes mellitus on white matter hyperintensity volume. Stroke 45:255–257

    Article  Google Scholar 

  40. Bekkelund SI, Pierre-Jerome C, Husby G, Mellgren SI (1995) Quantitative cerebral MR in rheumatoid arthritis. Am J Neuroradiol 16:767–772

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey

    Sinem Sağ, Ibrahim Tekeoğlu, Ayhan Kamanlı & Kemal Nas

  2. Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Sakarya University Research and Training Hospital, Sakarya, Turkey

    Mustafa Serdar Sağ

  3. Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey

    Bilgehan Atilgan Acar

Authors
  1. Sinem Sağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Serdar Sağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ibrahim Tekeoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayhan Kamanlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kemal Nas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bilgehan Atilgan Acar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sinem Sağ.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sağ, S., Sağ, M.S., Tekeoğlu, I. et al. Central nervous system involvement in rheumatoid arthritis: possible role of chronic inflammation and tnf blocker therapy. Acta Neurol Belg 120, 25–31 (2020). https://doi.org/10.1007/s13760-017-0879-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-017-0879-3

Keywords

Search

Navigation